Sex, myelin, and clinical characteristics of Parkinson's disease

Jiayue Cai1,2, Jowon L Kim2, Yuheng Wang3

  • 1School of Biomedical Engineering, Shenzhen University Medical School, Shenzhen University, Shenzhen, Guangdong, China.

PubMed
Abstract

Insights

Sex differences in Parkinson's disease (PD) involve myelin changes, impacting motor symptoms. Males showed greater overall myelin water fraction (MWF) and asymmetry, linked to motor performance differences.

Area of Science:

  • Neuroimaging
  • Neurology
  • Biomedical Engineering

Background:

  • Parkinson's disease (PD) exhibits sex-based differences in clinical presentation.
  • The role of myelin integrity in these sex disparities within PD is not well understood.

Purpose of the Study:

  • To investigate sex differences in myelin content in Parkinson's disease.
  • To determine if myelin alterations correlate with observed sex-based clinical variations in PD patients.

Main Methods:

  • Utilized myelin water fraction (MWF) MRI to assess myelin content in 33 Parkinson's disease subjects (23 males, 10 females).
  • Analyzed MWF across 20 white matter regions of interest (ROIs) and correlated findings with motor symptoms (UPDRS).
  • Employed statistical analyses including principal component analysis, regression, and t-tests to identify sex-specific differences and clinical associations.

Main Results:

  • Significant differences in MWF were observed in multiple white matter tracts, predicting biological sex.
  • Males exhibited greater overall MWF and asymmetry compared to females.
  • Specific white matter MWF variations were associated with tremor and asymmetric motor performance.

Conclusions:

  • Sex differences in myelin integrity are linked to distinct motor symptoms and performance asymmetry in Parkinson's disease.
  • These findings suggest biological sex plays a role in PD's myelin pathology and clinical manifestations, warranting further research.

Related Concept Videos

Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
590
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
292
Neural Regulation01:37

Neural Regulation

Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.5K
Excitatory and Inhibitory Effects of Neurotransmitters01:29

Excitatory and Inhibitory Effects of Neurotransmitters

When an action potential reaches the presynaptic axon terminal, it releases neurotransmitters from the neuron into the synaptic cleft at a chemical synapse. The released neurotransmitter can be excitatory or inhibitory. The critical criteria commonly used to determine whether a molecule is a neurotransmitter at a chemical synapse are the molecule's presence in the presynaptic neuron. Second, its release is in response to strong presynaptic depolarization. And lastly, the presence of...
10.1K